{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:18:23Z","timestamp":1791584303453,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","award":["INSPIRE Internship"],"award-info":[{"award-number":["INSPIRE Internship"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40273-025-01472-5","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T02:13:12Z","timestamp":1739326392000},"page":"499-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0066-509X","authenticated-orcid":false,"given":"Jeremiah","family":"Donoghue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Youngs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Vydyula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2409-4246","authenticated-orcid":false,"given":"Natalia","family":"Kunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7273-1463","authenticated-orcid":false,"given":"Roochi","family":"Trikha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-9384","authenticated-orcid":false,"given":"Daniel","family":"Gallacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"1472_CR1","unstructured":"NICE. Iptacopan for treating paroxysmal nocturnal haemoglobinuria: a single technology appraisal (TA1000); https:\/\/www.nice.org.uk\/guidance\/ta1000\/history. Accessed 15 Oct 2024."},{"key":"1472_CR2","unstructured":"NICE. Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria: a single technology appraisal (TA1010); https:\/\/www.nice.org.uk\/guidance\/ta1010\/history. Accessed 15 Oct 2024."},{"issue":"2","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bjh.17753","volume":"196","author":"AM Risitano","year":"2022","unstructured":"Risitano AM, PeffaultLatour R. How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol. 2022;196(2):288\u2013303.","journal-title":"Br J Haematol"},{"key":"1472_CR4","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028.","journal-title":"Nat Rev Dis Primers"},{"key":"1472_CR5","unstructured":"Shah, N, Bhatt, H. Paroxysmal nocturnal hemoglobinuria. In: StatPearls [Internet]. StatPearls Publishing, 2023."},{"key":"1472_CR6","volume-title":"Immunobiology: the immune system in health and disease","author":"C Janeway","year":"2001","unstructured":"Janeway C, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease. New York: Garland Pub; 2001."},{"issue":"25","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","volume":"121","author":"A Hill","year":"2013","unstructured":"Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985\u201396.","journal-title":"Blood"},{"issue":"2","key":"1472_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.13640","volume":"107","author":"SJ Richards","year":"2021","unstructured":"Richards SJ, Painter D, Dickinson AJ, et al. The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK\u2019s population-based haematological malignancy research network 2004\u20132018. Eur J Haematol. 2021;107(2):211\u20138.","journal-title":"Eur J Haematol"},{"issue":"4","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/ejh.13816","volume":"109","author":"J Panse","year":"2022","unstructured":"Panse J, Sicre de Fontbrune F, Burmester P, et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life. Eur J Haematol. 2022;109(4):351\u201363.","journal-title":"Eur J Haematol"},{"issue":"18","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311.","journal-title":"Blood"},{"issue":"6","key":"1472_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3324\/haematol.2010.023176","volume":"95","author":"RA Brodsky","year":"2010","unstructured":"Brodsky RA. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2010;95(6):855\u20136.","journal-title":"Haematologica"},{"issue":"10","key":"1472_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood.2019003812","volume":"137","author":"RA Brodsky","year":"2021","unstructured":"Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(10):1304\u20139.","journal-title":"Blood"},{"key":"1472_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","volume":"10","author":"AM Risitano","year":"2019","unstructured":"Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.","journal-title":"Front Immunol"},{"issue":"S4","key":"1472_CR14","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1002\/ajh.26882","volume":"98","author":"AG Kulasekararaj","year":"2023","unstructured":"Kulasekararaj AG, Lazana I. Paroxysmal nocturnal hemoglobinuria: where are we going. Am J Hematol. 2023;98(S4):S33\u201343.","journal-title":"Am J Hematol"},{"issue":"12-b Suppl","key":"1472_CR15","first-page":"S8","volume":"26","author":"M Bektas","year":"2020","unstructured":"Bektas M, Copley-Merriman C, Khan S, et al. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020;26(12-b Suppl):S8-s14.","journal-title":"J Manag Care Spec Pharm"},{"issue":"23","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood.2021014868","volume":"139","author":"GF Gerber","year":"2022","unstructured":"Gerber GF, Brodsky RA. Pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Blood. 2022;139(23):3361\u20135.","journal-title":"Blood"},{"key":"1472_CR17","unstructured":"NICE. NICE health technology evaluations: the manual. 2022."},{"key":"1472_CR18","unstructured":"NICE. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria: a single technology appraisal (TA778); https:\/\/www.nice.org.uk\/guidance\/ta778\/history. Accessed 15 Oct 2024."},{"issue":"11","key":"1472_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028\u201337.","journal-title":"N Engl J Med"},{"issue":"15","key":"1472_CR20","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","volume":"6","author":"JH Jang","year":"2022","unstructured":"Jang JH, Wong L, Ko BS, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6(15):4450\u201360.","journal-title":"Blood Adv"},{"issue":"12","key":"1472_CR21","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","volume":"10","author":"JW Lee","year":"2023","unstructured":"Lee JW, Griffin M, Kim JS, et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. The Lancet Haematology. 2023;10(12):e955\u201365.","journal-title":"The Lancet Haematology"},{"issue":"11","key":"1472_CR22","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","volume":"390","author":"R Latour","year":"2024","unstructured":"Latour R, R\u00f6th A, Kulasekararaj AG, et al. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2024;390(11):994\u20131008.","journal-title":"N Engl J Med"},{"issue":"13","key":"1472_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2217\/cer-2022-0076","volume":"11","author":"Z Hakimi","year":"2022","unstructured":"Hakimi Z, Wilson K, McAughey E, et al. The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting. J Comp Eff Res. 2022;11(13):969\u201385.","journal-title":"J Comp Eff Res"},{"issue":"6","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530\u20139.","journal-title":"Blood"},{"issue":"6","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540\u20139.","journal-title":"Blood"},{"key":"1472_CR26","unstructured":"SCAN, E. Health technology reassessment: An overview of Canadian and international processes. 2019."},{"issue":"3","key":"1472_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1046\/j.1524-4733.2001.43079.x","volume":"4","author":"M Buxton","year":"2001","unstructured":"Buxton M. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE). Value Health. 2001;4(3):212\u20136.","journal-title":"Value Health"},{"issue":"5","key":"1472_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s41669-024-00490-x","volume":"8","author":"D Lee","year":"2024","unstructured":"Lee D, Burns D, Wilson E. NICE\u2019s pathways pilot: pursuing good decision making in difficult circumstances. PharmacoEconomics - Open. 2024;8(5):645\u20139.","journal-title":"PharmacoEconomics - Open"},{"key":"1472_CR29","unstructured":"Taylor, P. Sanofi wins appeal in spat with NICE over Sarclisa. Pharmaphorum; 2024. https:\/\/pharmaphorum.com\/news\/sanofi-wins-appeal-spat-nice-over-sarclisa. Accessed 4 Feb 2025."},{"key":"1472_CR30","unstructured":"NICE. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy: Appeal Documents; 2020. https:\/\/www.nice.org.uk\/guidance\/ta692\/history. Accessed 2 Feb 2025."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01472-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T05:12:49Z","timestamp":1747890769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01472-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01472-5","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"19 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MY and AR were supported by INSPIRE funding provided by the Academy of Medical Sciences. No other funding was received for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DG was a member of the EAG for the appraisal of danicopan, and NK was a member of the EAG for the appraisal of iptacopan.\u00a0RT has received honoraria from Alexion, Swedish Orphan Biovitrum, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"DG generated the research idea and led the production of the manuscript. MY, AR and JD systematically reviewed and extracted the relevant trial and appraisal documents. SV, RT and NK contributed to the development of the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials and Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}